BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32250727)

  • 21. Gallium-68-prostate-specific membrane antigen (
    van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L
    BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
    Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
    Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using
    Nehra A; Parker WP; Haloi R; Park SS; Mynderse LA; Lowe VJ; Davis BJ; Quevedo JF; Johnson GB; Kwon ED; Karnes RJ
    J Urol; 2018 Mar; 199(3):726-733. PubMed ID: 28916273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imaging of Prostate Specific Membrane Antigen Targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis.
    Tan N; Bavadian N; Calais J; Oyoyo U; Kim J; Turkbey IB; Mena E; Davenport MS
    J Urol; 2019 Aug; 202(2):231-240. PubMed ID: 30829130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA ≤ 1 ng/mL After Definitive Primary Treatment.
    England JR; Paluch J; Ballas LK; Jadvar H
    Clin Nucl Med; 2019 Mar; 44(3):e128-e132. PubMed ID: 30589673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early lesion detection with
    Wondergem M; Jansen BHE; van der Zant FM; van der Sluis TM; Knol RJJ; van Kalmthout LWM; Hoekstra OS; van Moorselaar RJA; Oprea-Lager DE; Vis AN
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1911-1918. PubMed ID: 31230088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy, Predictive Factors, and Prediction Nomograms for
    Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of Biochemically Recurrent Prostate Cancer with [
    Sadaghiani MS; Sheikhbahaei S; Al-Zaghal A; Solnes LB; Pomper MG; Oldan JD; Ulaner GA; Gorin MA; Rowe SP
    Tomography; 2023 Aug; 9(4):1504-1514. PubMed ID: 37624113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How does
    Bianchi L; Schiavina R; Borghesi M; Ceci F; Angiolini A; Chessa F; Droghetti M; Bertaccini A; Manferrari F; Marcelli E; Cochetti G; Porreca A; Castellucci P; Fanti S; Brunocilla E
    Int J Urol; 2019 Aug; 26(8):804-811. PubMed ID: 31083784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
    Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
    Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective Evaluation of
    Song H; Harrison C; Duan H; Guja K; Hatami N; Franc BL; Moradi F; Aparici CM; Davidzon GA; Iagaru A
    J Nucl Med; 2020 Apr; 61(4):546-551. PubMed ID: 31628216
    [No Abstract]   [Full Text] [Related]  

  • 32. Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer.
    Savir-Baruch B; Lovrec P; Solanki AA; Adams WH; Yonover PM; Gupta G; Schuster DM
    AJR Am J Roentgenol; 2019 Oct; 213(4):851-858. PubMed ID: 31216198
    [No Abstract]   [Full Text] [Related]  

  • 33. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer.
    Pruthi RS; Johnstone I; Tu IP; Stamey TA
    Urology; 1997 May; 49(5):737-42. PubMed ID: 9145980
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Lopci E; Saita A; Lazzeri M; Lughezzani G; Colombo P; Buffi NM; Hurle R; Marzo K; Peschechera R; Benetti A; Zandegiacomo S; Pasini L; Lista G; Cardone P; Castello A; Maffei D; Balzarini L; Chiti A; Guazzoni G; Casale P
    J Urol; 2018 Jul; 200(1):95-103. PubMed ID: 29409824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group.
    Teeter AE; Griffin K; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ
    J Urol; 2018 Mar; 199(3):713-718. PubMed ID: 28870860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
    Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
    Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy.
    Okotie OT; Aronson WJ; Wieder JA; Liao Y; Dorey F; DeKERNION JB; Freedland SJ
    J Urol; 2004 Jun; 171(6 Pt 1):2260-4. PubMed ID: 15126798
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Eiber M; Kroenke M; Wurzer A; Ulbrich L; Jooß L; Maurer T; Horn T; Schiller K; Langbein T; Buschner G; Wester HJ; Weber W
    J Nucl Med; 2020 May; 61(5):696-701. PubMed ID: 31836682
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.